Epiva Biosciences has merged with Evelo Biosciences INC to create an immune-microbiome company for the development of therapeutics for cancer, autoimmune and inflammatory diseases.

According to the agreement, the combined company will retain the name of Evelo Biosciences and establish a metasystem combining the microbiome and immune system platforms of both organisations.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Ningbo Medical System Biotechnology has announced its acquirement of an 80% stake in Shanghai Biological Engineering Co. Ltd.

"Ningbo Medical System Biotechnology has announced its acquirement of an 80% stake in Shanghai Biological Engineering Co. Ltd."

The company expects to acquire it for a purchase consideration of $1.46m.

Martindale Pharmaceuticals has acquired Viridian Pharma Limited in order to expand its product portfolio and support the growth of its hospital initiated medicines product range.

According to the agreement, Viridian Pharma will be combined into Martindale Pharma’s existing growing business.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The acquisition will immediately be accretive to the gross earnings.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact